Mitoquinone mesylate (also known as MitoQ) is a mitochondria-targeted antioxidant derived from coenzyme Q10. Its primary scientific rationale for use in liver detoxification stems from research into its effects on mitochondrial oxidative stress, which is implicated in various liver diseases. Preclinical studies in animal models have shown that MitoQ can reduce oxidative damage in the liver, improve mitochondrial function, and may attenuate fibrosis and inflammation in models of non-alcoholic fatty liver disease (NAFLD) and toxin-induced liver injury. For example, studies published in journals such as Hepatology and Free Radical Biology & Medicine have demonstrated that MitoQ administration in rodents can decrease markers of liver oxidative stress and improve histological features associated with liver damage.

However, direct clinical evidence in humans for MitoQ supporting or enhancing “liver detoxification” is limited. While a few small trials have explored its safety and general antioxidant effects in people with liver conditions (e.g., hepatitis C, NAFLD), robust, large-scale clinical trials demonstrating clear liver detoxification or enhanced liver function outcomes are lacking as of 2024. Thus, while there is scientific plausibility and some preclinical support, the evidence base remains preliminary, and efficacy in humans is not well established. MitoQ’s use for “liver detoxification” should be regarded as experimental and not as a standard, validated therapy.